J. Collins

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Accelerated titration designs for phase I clinical trials in oncology.

R Simon, R. Simon, M. Christian, 1997, Journal of the National Cancer Institute.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

J. Forbes, F. Cavalli, R. Gelber, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

A. Goldhirsch, A. Coates, B. Thürlimann, 1998, European journal of cancer.

Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)

R. Gelber, A. Goldhirsch, M. Castiglione, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2004, British Journal of Cancer.

Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

A. Goldhirsch, A. Coates, B. Thürlimann, 1998 .

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer.

L. Eapen, J. Collins, D. Stewart, 2004, The Journal of urology.

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.

M. Tattersall, R. Gelber, A. Goldhirsch, 1997, European journal of cancer.

Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review.

J. Collins, A. Nyboe Andersen, J. Arce, 2005, Human reproduction.

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group).

F. Cavalli, R. Gelber, A. Goldhirsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of Clinical Oncology.

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.

A. Goldhirsch, J. Collins, A. Coates, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer : Results of the International Breast Cancer Study Group ( IBCSG ) Trial

F. Cavalli, A. Goldhirsch, M. Castiglione, 2005 .

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence o f E ndocrine-Relate d F actors o n R esponse t o Perioperative C hemotherapy f or P atients W ith N ode- Negative B reast C ancer

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

R. Gelber, A. Goldhirsch, A. Coates, 2000, The Lancet.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

M. Bonetti, R. Gelber, A. Goldhirsch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, R. Gelber, A. Goldhirsch, 1998, European journal of cancer.

Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial.

R. Gelber, A. Goldhirsch, C. Hürny, 1996, Medical care.

Original article: Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance

F. Cavalli, A. Goldhirsch, M. Castiglione, 1992 .

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF

M. Bonetti, R. Gelber, W. Sauerbrei, 2002, British Journal of Cancer.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Between Cholecystectomy and Intestinal Cancer: A National Record Linkage Study

M. Goldacre, J. Collins, C. Wotton, 2012, Annals of surgery.

Effect of systemic adjuvant treatment on first sites of breast cancer relapse

G Marini, M. Tattersall, J. Forbes, 1994, The Lancet.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

Oestrogen and Endometrial Cancer: A Reappraisal

J. Collins, J. Collins, 1981, Journal of the Royal Society of Medicine.

The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1995, Israel journal of medical sciences.

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncologic outcomes of patients with incidental prostate cancer who underwent RARC: a comparison between nerve sparing and non-nerve sparing approach

P. Wiklund, M. Aly, J. Collins, 2020, Journal of Robotic Surgery.

Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomized trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate and 5-fluorouracil)

M. Bonetti, R. Gelber, W. Sauerbrei, 2002 .

10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection

M. Stockler, V. Gebski, G. Farshid, 2023, Breast.

Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer

R. Gelber, A. Goldhirsch, A. Coates, 2006, Cancer.

Primary results of ANZ 1002: Post-operative radiotherapy omission in selected patients with early breast cancer trial (PROSPECT) following pre-operative breast MRI.

V. Gebski, A. Rose, Arlene Mou, 2022, Journal of Clinical Oncology.

Early S tart o f A djuvant C hemotherapy M ay I mprove Treatment O utcome f or P remenopausal B reast C ancer Patients W ith T umors n ot E xpressing E strogen R eceptors

M. Bonetti, R. Gelber, A. Coates, 2000 .